Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors

Trial Profile

Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs ISA 101 (Primary) ; Nivolumab
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 07 Dec 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 12 Sep 2017 Primary endpoint has been met. (Overall Response Rate (ORR)), according to results presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top